Company news

Quantum Cyber N.V. news in 2022

Quantum Cyber N.V.'s news releases, calls and decks from 2022, newest first.

View company

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

December 19, 2022

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

December 5, 2022

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

November 28, 2022

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

November 14, 2022

Mainz Biomed Provides Third Quarter 2022 Update

November 1, 2022

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

September 27, 2022

Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board

September 19, 2022

Mainz Biomed Reports First Half 2022 Financial Results

September 6, 2022

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

August 15, 2022

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

August 2, 2022

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

July 18, 2022

Mainz Biomed Today to Provide Corporate Update for First Half of 2022

July 11, 2022

Mainz Biomed Provides Corporate Update for First Half of 2022

July 4, 2022

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

June 27, 2022

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

June 13, 2022

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

May 31, 2022

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

May 18, 2022

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

May 8, 2022

Mainz Biomed Provides Product Development Update on PancAlert

May 4, 2022

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

April 25, 2022

Mainz Biomed Announces First Quarter 2022 Results

April 11, 2022

Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial

March 30, 2022

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

March 20, 2022

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

March 16, 2022

Mainz Biomed Announces Year End 2021 Results

March 8, 2022

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

March 1, 2022

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

February 22, 2022

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

February 13, 2022

Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board

February 8, 2022

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

February 3, 2022

Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 27, 2022

Mainz Biomed Appoints Steve Quinn as VP Business Development

January 26, 2022

Mainz Biomed Announces Pricing of Follow-on Offering

January 25, 2022

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

January 18, 2022

Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board

January 11, 2022

Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

January 4, 2022